Founded in 1978 in Hyderabad, India, Gland Pharma has evolved from a contract manufacturer of small-volume liquid parenterals into one of the world’s leading and fastest-growing producers of generic injectables, serving over 60 countries, including the US, Europe, Canada, Australia, and India.
Operating under a primarily B2B model, Gland Pharma has built a strong reputation for excellence in R&D, manufacturing, and marketing of complex injectable pharmaceuticals.
Our end-to-end presence in the pharmaceutical value chain has fueled our rapid and sustained growth over the years.
Gland Pharma boasts a professional leadership team, with Shanghai Fosun Pharma, a major global pharmaceutical company, as one of its key promoters.
Our core therapeutic areas include sterile injectables, oncology, and ophthalmology, with a focus on complex formulations such as NCE-1s, First-to-File products, and 505(b)(2) applications.
We currently offer our injectables in various formats, including liquid and lyophilized vials, pre-filled syringes, ampoules, infusion bags, and eye drops.
To expand our capabilities, we are actively investing in the development of advanced formulations, including peptides, long-acting injectables, hormonal products, and suspensions.
As part of our pipeline expansion, we are also introducing innovative delivery systems like pens and cartridges to better meet diverse patient needs.
